Lee, J. S., & Manegold, C. (2012). Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: A randomized, double-blind phase III trial (ZEPHYR). Journal of clinical oncology, 30(10), . https://doi.org/10.1200/JCO.2011.36.1709
Chicago-Zitierstil (17. Ausg.)Lee, Jin Soo, und Christian Manegold. "Vandetanib Versus Placebo in Patients with Advanced Non-small-cell Lung Cancer After Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-blind Phase III Trial (ZEPHYR)." Journal of Clinical Oncology 30, no. 10 (2012). https://doi.org/10.1200/JCO.2011.36.1709.
MLA-Zitierstil (9. Ausg.)Lee, Jin Soo, und Christian Manegold. "Vandetanib Versus Placebo in Patients with Advanced Non-small-cell Lung Cancer After Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-blind Phase III Trial (ZEPHYR)." Journal of Clinical Oncology, vol. 30, no. 10, 2012, https://doi.org/10.1200/JCO.2011.36.1709.